Previous 10 | Next 10 |
home / stock / bayry / bayry news
Recursion Pharma is hoping to revolutionize drug discovery with its Recursion OS technology; potential to improve drug discovery and processing capabilities. Recent deal with Roche brought in an upfront payment of $150 million, with potential to earn up to $300 million for each of the...
Inflation concerns have started to affect market sentiment, but it is highly uncertain if that will lead to a real market correction or just some short-term dips. I am continuing my monthly investment plans while still awaiting a market correction or possibly a real crash once market ...
Harris Associates’ 13F portfolio value decreased from $62.80B to $62.77B this quarter. They increased Fiserv, Humana, and Alibaba while decreasing CNH Industrial, Liberty Global, and Automatic Data Processing. The top three positions are Alphabet, Bank of America, and Chart...
BELLUS achieved primary endpoint of phase 2b SOOTHE study using BLU-5937 in patients with refractory chronic cough. An end of phase 2b meeting with the FDA for BLU-5937 in refractory chronic cough is expected in Q2 of 2022, with phase 3 study likely to start in 2nd half of 2022. T...
Bayer (OTCPK:BAYRY) wins its second straight victory in a trial over claims its Roundup weedkiller causes cancer, as a California jury finds the product did not cause a woman's non-Hodgkin's lymphoma. The woman had sued the company for negligence and failing to warn her of the dangers of Roun...
Nubeqa (darolutamide), developed by Bayer (OTCPK:BAYRY) (OTCPK:BAYZF) and Orion Corporation, has met the primary endpoint in a Phase 3 trial involving patients with hormone-sensitive prostate cancer ((mHSPC)). In the ARASENS trial, darolutamide in combination with docetaxel and androgen depri...
Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your time for further analy...
Inflation concerns have started to affect market sentiment, but it is highly uncertain if that will lead to a real market correction or just some short-term dips. I am continuing my monthly investment plans while still awaiting a market correction or possibly a real crash once market ...
Narrow AI is trained to solve problems and adapt to change using the concept of machine learning. AI algorithms analyse previous actions and can autonomously improve when given new datasets. AI can analyse vast quantities of data, allowing it to identify patterns in datasets that are ...
ESSA Pharma developed a novel mode of action drug, EPI-7386, for the treatment of metastatic castrate-resistant prostate cancer. Pre-clinical and early Ph 1 results are promising. ESSA's share price crashed in mid-Aug when a change in the Ph 1 trial protocol was announced, and a delay...
News, Short Squeeze, Breakout and More Instantly...
Bayer AG ADR Company Name:
BAYRY Stock Symbol:
OTCMKTS Market:
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...